Trial Profile
Effect of aflibercept in wet age-related macular degenaration (wAMD) with retinal pigment epithelium detachment (PED)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Aug 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 30 Jul 2018 Status changed from not yet recruiting to discontinued.
- 17 May 2016 New trial record